[The application of artificial dermis and recombinant bFGF afer immersion bath in residual burn wound].
OBJECTIVE
To observe the effect of application of a new type of artificial biological dressing and recombinant bull fibroblast growth factor( rb-FGF2) after immersion bath in the treatment of residual infected burn wounds at late postburn stage.


METHODS
Fifty-six patients with residual wounds at late postburn stage were enrolled in the study, and they were randomly divided into A( n = 28, experimental) and B (n = 28, control) groups. After treatment with immersion bath, the wounds in group A were treated with semi-exposure method. The wound were covered with suitable shape of biological dressings in suitable shape and rb-FGF2 spray twice a day after an immersion bath, and the dressing was changed every other day or every 2 days. To compare the treatment effect, the wounds in group B were only treated with a dressing of monolayer gauze wetted with povidone iodine. The clinical results, the bacteriological state findings, and the corresponding safety indices were determined 10 days after treatment.


RESULTS
The wound healing rate, efficacy and the bacterial clearance rate in A group were 64. 3% ,89. 3% ,92. 3% , respectively, and they were obviously higher than those in B group (32. 1% , 67. 9% , 72. 0% , respectively, P < 0. 01 ). No adverse side-effects were observed in either group.


CONCLUSIONS
Application of artificial dermis and bFGF after immersion bath is safe and effective for the elimination of residual wounds at late postburn stage, and it is also beneficial to control wound infection and promote the wound healing.
Gao
Wei-dong
WD
Institute of Burn Research, Southwest Hospital , State Key Laboratory of Trauma , Burns and Combine Injury, the Third Military Medical University, Chongqing 400038 , PR China.
Liu
Xu-sheng
XS
Han
Xing
X
Han
Yu-guo
YG
Yu
Ji-chao
JC
D000328:Adult; D001494:Baths; D001684:Biological Dressings; D002056:Burns / Q000628:therapy*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D017768:Skin, Artificial; D014945:Wound Healing
D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2